Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Central nervous system germ cell tumours (germinoma and non-germinomatous), drawn from the whole corpus: 2 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Which non-germinomatous patients can safely avoid craniospinal irradiation.
Late endocrine, cognitive and vascular effects of radiotherapy in survivors treated as teenagers.
Relapsed non-germinomatous tumours have poor salvage rates.
Nothing recorded yet.
Also on OnCo: Treatment journeys · Survivorship planner.
Why incidence is several times higher in East Asia.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 8 changes by month →When this page itself was last checked or edited.
A milestone in how this cancer is treated.
Three-year progression-free survival 87.
74 of 85 evaluable patients responded to induction chemotherapy; three-year progression-free survival 92 percent and overall survival 94.
Goldman and colleagues (JCO).
Calaminus and colleagues (Neuro-Oncology): equivalent survival, more ventricular relapses with focal fields; whole-ventricular irradiation adopted.